Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug:14:100303.
doi: 10.1016/j.jvacx.2023.100303. Epub 2023 Apr 15.

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia

Norazida Ab Rahman  1 , Ming Tsuey Lim  1 , Fei Yee Lee  2 , Emelyne Bani Anak Jam  3 , Kalaiarasu M Peariasamy  1 , Sheamini Sivasampu  1 ; SAFECOVAC study group
Affiliations

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia

Norazida Ab Rahman et al. Vaccine X. 2023 Aug.

Abstract

This study evaluates 21-day risk of myocarditis/pericarditis following COVID-19 vaccination among those aged 12 years and older in Malaysia. We used data from nationwide COVID-19 vaccine registry linked to hospital episode database to identify individuals vaccinated with BNT162b2, CoronaVac, or ChAdOx1 and hospitalised for myocarditis/pericarditis between 1 February 2021 and 28 February 2022. There were 87 myocarditis/pericarditis cases identified within 1-21 days after vaccination. Most cases were reported following BNT16262 vaccination (77.0%) with absolute risk of 0.33 cases/100,000 vaccinated persons or 1.73 per million doses administered. Highest risk was observed following second dose and in younger, male individuals. The risk of myocarditis/pericarditis following CoronaVac and ChAdOx1 were much lower compared to BNT162b2. The findings on higher risk observed among younger following mRNA vaccine were consistent with literature and important for targeted surveillance.

Keywords: Adverse effects; COVID-19 vaccine; Myocarditis; Pericarditis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Flowchart of inclusion and exclusion criteria for analysis.
Fig. 2
Fig. 2
Cumulative incidence (risk) of myocarditis/pericarditis within 1–21 days after BNT162b2 vaccine, stratified by vaccine dose, sex, and age. Risks are described as risk per 100,000 vaccinated persons and the corresponding 95% confidence interval (CI).
See this image and copyright information in PMC

References

    1. Wang X., Bu X., Wei L., Liu J., Yang D., Mann D.L., et al. Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017. Front Cardiovasc Med. 2021;8 - PMC - PubMed
    1. Bozkurt B., Kamat I., Hotez P.J. Myocarditis With COVID-19 mRNA Vaccines. Circulation. 2021;144(6):471–484. - PMC - PubMed
    1. Karlstad Ø., Hovi P., Husby A., Härkänen T., Selmer R.M., Pihlström N., et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. 2022;7(6):600–612. - PMC - PubMed
    1. EMA/PRAC/683817/2021. Signal assessment report on Myocarditis, pericarditis with Tozinameran (COVID-19 mRNA vaccine (nucleoside modified) – COMIRNATY) 2021 [Available from: https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assess....
    1. Pillay J., Gaudet L., Wingert A., Bialy L., Mackie A.S., Paterson D.I., et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. BMJ (Clinical research ed) 2022;378:e069445. - PMC - PubMed

LinkOut - more resources